Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients

N/ACompletedNCT04043793
University Hospital, Lille759 enrolled

Overview

the number of immunocompromised patients hospitalized in the intensive care units (ICU) is increasing. They are at higher risk of colonization and/or infection with multi-resistant bacteria (MDR). However this risk is not well characterized. ICU acquired infections related to MDR are associated with increased morbidity and mortality. The aim of this study is to compare the incidence of ICU-acquired colonization and ICU-acquired infection related to MDR between immunocompromized and immunocompetent patients. The risk factors for ICU-acquired colonization and ICU-acquired infections, and their impact on outcome will also be evaluated and compared between immunocompromised and immunocompetent patients.

Study Type

OBSERVATIONAL

Enrollment

759

Conditions

Immunocompromised HostCritical Care

Eligibility

Sex: ALLMin age: 18 Years
Medical Language ↔ Plain English
Inclusion Criteria: * Expected ICU stay \> 48 hours * All patients (immunocompromised or immunocompetent). Exclusion Criteria: * Patients aged \< 18 years * Refusal to take part in the study * ICU-stay \< 48 hours * Non availability of initial MDR or subsequent screening * Participation in another study that could interfere with the risk of ICU-acquired colonization and infection with MDR bacteria

Locations (7)

Chu Amiens Picardie

Amiens, France

Ch Bethune

Béthune, France

Grand Hopital de L'Est Francilien

Jossigny, France

CH LENS

Lens, France

Hôpital Roger Salengro, CHU

Lille, France

Hospices Civils de Lyon

Lyon, France

C.H de Roubaix

Roubaix, France

Outcomes

Primary Outcomes

Density rate of ICU-acquired infections related to MDR in immunosuppressed patients.

the number ICU-acquired infections related to MDR will be devided by the number of days in the ICU and reported for 1000 days.

Time frame: From ICU admission until day 28 after ICU admission

Secondary Outcomes

Density rate of ICU-acquired colonizations related to MDR in immunosuppressed patients

the number of ICU-acquired colonizations related to MDR will be devided by the number of days in the ICU and reported for 1000 days

Time frame: From ICU admission until day 28 after ICU admission

Rate of ICU-acquired colonizations related to MDR in immunosuppressed patients.

The rate of patients with at least one ICU-acquired colonization related to MDR

Time frame: From ICU admission until day 28 after ICU admission

Rate of ICU-acquired infections related to MDR in immunosuppressed patients

The rate of patients with at least one ICU-acquired infection related to MDR

Time frame: From ICU admission until day 28 after ICU admission

28 day mortality

death in the ICU or after discharge from the ICU

Time frame: from ICU admission until day 28 after admission

Mechanical ventilation duration

the number of days Under mechanical ventilation

Time frame: From ICU admission until day 28 after ICU admission

length of stay in intensive care unit

the number of days of hospitalization in teh ICU

Time frame: From ICU admission until day 28 after ICU admission

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.